A Phase 4 interventional study of Nivolumab and Ipilimumab in Kidney Neoplasms, sponsored by Bristol-Myers Squibb. Completed at 11 sites in India. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing nivolumab in Kidney Neoplasms — 4 open to participants now, 7 under way, 2 of them phase 3. Nivolumab · Kidney Neoplasms.
Among the 19 studies testing nivolumab in Kidney Neoplasms, this one is the 5th largest by enrollment, is one of 4 that started in 2020, is one of 4 in phase 4, and was the 13th registered.
969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.
Browse Kidney Neoplasms studies →4 of the 19 studies testing nivolumab in Kidney Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 70+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
Guliz Ozgun · Sites in Canada
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 46 across 668 interventional studies indexed under Kidney Neoplasms.
Median enrollment 50 across the 19 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
14 studies in Kidney Neoplasms by Bristol-Myers Squibb: 1 open now, 1 under way, none of them phase 3. Of 13 finished, 4 (31%) have results posted.
Among the 14 studies in Kidney Neoplasms by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2020, is one of 2 in phase 4, and was the 13th registered.
Bristol-Myers Squibb’s Kidney Neoplasms studies by the year they started, since 2004.
1 of the studies testing nivolumab in Kidney Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04322955Mark SteinCYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing nivolumab in Kidney Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 14 in Kidney Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of nivolumab combined with ipilimumab in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC) or metastatic RCC (mRCC) in India.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Biological: Ipilimumab
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Specified dose on specified days
Also known as: BMS-734016, Yervoy
Total Number of Participants Experiencing High Grade Immune-Mediated Adverse Events (IMAE)
IMAEs are a type of adverse event that occurs when the immune system reacts against the body's own tissues, including diarrhea/colitis, hepatitis, pneumonitis, nephritis and renal dysfunction, rash, and endocrine (adrenal insufficiency, hypophysitis, hypothyroidism/thyroiditis, hyperthyroidism, and diabetes mellitus). IMAE analyses includes events, regardless of causality, which occurred during the study and follow-up. Only participants who received immune-modulating medication for treatment of the event are reported, with the exception of endocrine events, which will be included regardless of treatment since these events are often managed without immunosuppression. High grade (Grade 3 to 4 and Grade 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.
Time frame: From first dose until 100 days after the last dose or for a maximum of 52 weeks from the date of the first on-study dose of nivolumab, whichever occurs earlier.
Time to Onset of High Grade Immune-Mediated Adverse Event (IMAE)
Time to onset is defined as the time between the day of the first dose of study treatment and the onset date of the earliest AE (Grades 3-5) in this category. All IMAEs that occurred between first dose and 100 days past last dose are recorded. IMAEs are a type of adverse event that occurs when the immune system reacts against the body's own tissues. IMAE analyses includes events, regardless of causality, which occurred during the study and follow-up. Only participants who received immune-modulating medication for treatment of the event are reported, with the exception of endocrine events, which will be included regardless of treatment since these events are often managed without immunosuppression. High grade (Grades 3 through 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.
Time frame: From first dose until onset of IMAE (up to approximately 15 months)
Time to Resolution of High Grade Immune-Mediated Adverse Event (IMAE)
Time to resolution of IMAEs is defined as the longest time from onset to complete resolution or improvement to the grade at baseline among all clustered AEs experienced by the participant in this category per adverse event criteria category. Events which worsened into grade 5 events (death) or have a resolution date equal to the date of death are considered unresolved. If a clustered AE is considered as unresolved, the resolution date will be censored to the last known alive date. Improvement to the grade at baseline implies that all different events in the clustered adverse event should at least have improved to the corresponding (i.e. with same preferred term) baseline grade. High grade (Grades 3 through 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.
Time frame: From first dose until resolution of IMAE (up to approximately 15 months)
The Number of Participants Who Received Immune-Modulating Medication
Immune modulating medications are medications entered on an immune modulating medication form or available from the most current pre-defined list of immune modulating medications. This list is revisited whenever UMC WHO releases a new version and updated accordingly.
Time frame: From first dose up to 100 days after last dose (up to approximately 15 months)
Objective Response Rate (ORR)
Objective Response Rate (ORR) was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose up to 100 days after last dose (up to approximately 15 months)
Time to Response (TTR)
TTR is defined as the time from the date of first dose to the date of the first confirmed documented response (CR or PR). For the non-responders, TTR was censored at the maximum time of response + 1 day of all participants. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose to the date of CR or PR (up to approximately 15 months)
Duration of Response (DoR)
Duration of Response (DOR) is defined as the time between the date of first documented response (CR or PR) that was subsequently confirmed to the date of the first documented progression as determined using RECIST 1.1, or death due to any cause, whichever occurs first. For participants who neither progress nor die, the duration of response will be censored on the date of their last evaluable tumor assessment. For participants who start subsequent therapy before progression or die, the duration of response will be censored on the date of their last evaluable tumor assessment conducted on or prior to the initiation of the subsequent therapy. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Analysis based on Kaplan Meier estimates.
Time frame: From first documented response (CR or PR) up to first documented progression or death due to any cause, whichever occurs first (up to approximately 3 years)
| Milestone | Nivolumab + Ipilimumab |
|---|---|
| Started | 101 |
| Completed | 36 |
| Not completed | 65 |
| Withdrew: Other reasons | 1 |
| Withdrew: Adverse event unrelated to study drug | 9 |
| Withdrew: Study drug toxicity | 14 |
| Withdrew: Disease progression | 39 |
| Withdrew: Participants withdrew consent | 2 |
IMAEs are a type of adverse event that occurs when the immune system reacts against the body's own tissues, including diarrhea/colitis, hepatitis, pneumonitis, nephritis and renal dysfunction, rash, and endocrine (adrenal insufficiency, hypophysitis, hypothyroidism/thyroiditis, hyperthyroidism, and diabetes mellitus). IMAE analyses includes events, regardless of causality, which occurred during the study and follow-up. Only participants who received immune-modulating medication for treatment of the event are reported, with the exception of endocrine events, which will be included regardless of treatment since these events are often managed without immunosuppression. High grade (Grade 3 to 4 and Grade 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.
| Participants | Nivolumab + Ipilimumab |
|---|---|
| Pneumonitis Grade 3-4 | 2 |
| Nephritis and Renal Dysfunction Grade 3-4 | 1 |
| Rash Grade 3-4 | 2 |
| Adrenal Insufficiency Grade 3-4 | 1 |
| Diarrhea/Colitis Grade 3-5 | 0 |
| Hepatitis Grade 3-5 | 0 |
| Nephritis and Renal Dysfunction Grade 5 | 0 |
| Rash Grade 5 | 0 |
| Hypersensitivity Grade 3-5 | 0 |
| Adrenal Insufficiency Grade 5 | 0 |
| Hypothyroidism/Thyroiditis Grade 3-5 | 0 |
| Diabetes Mellitus Grade 3-5 | 0 |
| Hyperthyroidism Grade 3-5 | 0 |
| Hypophysitis Grade 3-5 | 0 |
Time to onset is defined as the time between the day of the first dose of study treatment and the onset date of the earliest AE (Grades 3-5) in this category. All IMAEs that occurred between first dose and 100 days past last dose are recorded. IMAEs are a type of adverse event that occurs when the immune system reacts against the body's own tissues. IMAE analyses includes events, regardless of causality, which occurred during the study and follow-up. Only participants who received immune-modulating medication for treatment of the event are reported, with the exception of endocrine events, which will be included regardless of treatment since these events are often managed without immunosuppression. High grade (Grades 3 through 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.
| Weeks | Nivolumab + Ipilimumab |
|---|---|
| ADRENAL INSUFFICIENCY | 9.9 (9.9 to 9.9) |
| PNEUMONITIS | 7.29 (1.4 to 13.1) |
| NEPHRITIS AND RENAL DYSFUNCTION | 20.00 (20.0 to 20.0) |
| RASH | 29.21 (29.0 to 29.4) |
Time to resolution of IMAEs is defined as the longest time from onset to complete resolution or improvement to the grade at baseline among all clustered AEs experienced by the participant in this category per adverse event criteria category. Events which worsened into grade 5 events (death) or have a resolution date equal to the date of death are considered unresolved. If a clustered AE is considered as unresolved, the resolution date will be censored to the last known alive date. Improvement to the grade at baseline implies that all different events in the clustered adverse event should at least have improved to the corresponding (i.e. with same preferred term) baseline grade. High grade (Grades 3 through 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.
| Weeks | Nivolumab + Ipilimumab |
|---|---|
| ADRENAL INSUFFICIENCY | 1.1 (1.1 to 1.1) |
| RASH | 10.07 (5.0 to 15.1) |
Immune modulating medications are medications entered on an immune modulating medication form or available from the most current pre-defined list of immune modulating medications. This list is revisited whenever UMC WHO releases a new version and updated accordingly.
| Participants | Nivolumab + Ipilimumab |
|---|---|
| The Number of Participants Who Received Immune-Modulating Medication | 38 |
Objective Response Rate (ORR) was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Nivolumab + Ipilimumab |
|---|---|
| Objective Response Rate (ORR) | 37.6 (27.4 to 48.8) |
TTR is defined as the time from the date of first dose to the date of the first confirmed documented response (CR or PR). For the non-responders, TTR was censored at the maximum time of response + 1 day of all participants. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Months | Nivolumab + Ipilimumab |
|---|---|
| Time to Response (TTR) | 2.79 (2.3 to 10.3) |
Duration of Response (DOR) is defined as the time between the date of first documented response (CR or PR) that was subsequently confirmed to the date of the first documented progression as determined using RECIST 1.1, or death due to any cause, whichever occurs first. For participants who neither progress nor die, the duration of response will be censored on the date of their last evaluable tumor assessment. For participants who start subsequent therapy before progression or die, the duration of response will be censored on the date of their last evaluable tumor assessment conducted on or prior to the initiation of the subsequent therapy. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Analysis based on Kaplan Meier estimates.
| Months | Nivolumab + Ipilimumab |
|---|---|
| Duration of Response (DoR) | NA (1.3 to 9.9) |
Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 3 years). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 15 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab + Ipilimumab | 11/101 (10.9%) | 37/101 (36.6%) | 80/101 (79.2%) |
| Event | Nivolumab + Ipilimumab |
|---|---|
| HyponatraemiaMetabolism and nutrition disorders | 5/101 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/101 |
| AnaemiaBlood and lymphatic system disorders | 3/101 |
| DeathGeneral disorders | 2/101 |
| Renal impairmentRenal and urinary disorders | 2/101 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/101 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/101 |
| Acute coronary syndromeCardiac disorders | 1/101 |
| Cardiac arrestCardiac disorders | 1/101 |
| Myocardial infarctionCardiac disorders | 1/101 |
| Event | Nivolumab + Ipilimumab |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 25/101 |
| PruritusSkin and subcutaneous tissue disorders | 21/101 |
| AstheniaGeneral disorders | 19/101 |
| PyrexiaGeneral disorders | 17/101 |
| AnaemiaBlood and lymphatic system disorders | 14/101 |
| Back painMusculoskeletal and connective tissue disorders | 13/101 |
| DiarrhoeaGastrointestinal disorders | 12/101 |
| RashSkin and subcutaneous tissue disorders | 12/101 |
| NauseaGastrointestinal disorders | 11/101 |
| FatigueGeneral disorders | 11/101 |
All treated participants
| Age, Continuous(Years) | Nivolumab + Ipilimumab |
|---|---|
| Mean | 56.0 ± 9.99 |
| Sex: Female, Male(Participants) | Nivolumab + Ipilimumab |
|---|---|
| Female | 22 |
| Male | 79 |
| Race/Ethnicity, Customized(Participants) | Nivolumab + Ipilimumab |
|---|---|
| Asian Indian | 101 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Jan 2024, 36 months.
Results were first posted in Jul 2025, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab